PT  - JOURNAL ARTICLE
AU  - Halliday, Alice
AU  - Long, Anna E
AU  - Baum, Holly E
AU  - Thomas, Amy C
AU  - Shelley, Kathryn L
AU  - Oliver, Elizabeth
AU  - Gupta, Kapil
AU  - Francis, Ore
AU  - Kavanagh Williamson, Maia
AU  - di Bartolo, Natalie
AU  - Randell, Matthew J
AU  - Ben-Khoud, Yassin
AU  - Kelland, Ilana
AU  - Mortimer, Georgina
AU  - Ball, Olivia
AU  - Plumptre, Charlie
AU  - Chandler, Kyla
AU  - Obst, Ulrike
AU  - Secchi, Massimiliano
AU  - Piemonti, Lorenzo
AU  - Lampasona, Vito
AU  - Smith, Joyce
AU  - Gregorova, Michaela
AU  - Knezevic, Lea
AU  - Metz, Jane
AU  - Barr, Rachael
AU  - Morales-Aza, Begonia
AU  - Oliver, Jennifer
AU  - Collingwood, Lucy
AU  - Hitchings, Benjamin
AU  - Ring, Susan
AU  - Wooldridge, Linda
AU  - Rivino, Laura
AU  - Timpson, Nicholas
AU  - McKernon, Jorgen
AU  - Muir, Peter
AU  - Hamilton, Fergus
AU  - Arnold, David
AU  - Woolfson, Derek N
AU  - Goenka, Anu
AU  - Davidson, Andrew D.
AU  - Toye, Ashley M
AU  - Berger, Imre
AU  - Bailey, Mick
AU  - Gillespie, Kathleen M
AU  - Williams, Alistair JK
AU  - Finn, Adam
TI  - Development and evaluation of low-volume tests to detect and characterise antibodies to SARS-CoV-2
AID  - 10.1101/2022.05.03.22274395
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.05.03.22274395
4099  - http://medrxiv.org/content/early/2022/05/05/2022.05.03.22274395.short
4100  - http://medrxiv.org/content/early/2022/05/05/2022.05.03.22274395.full
AB  - Low-volume antibody assays can be used to track SARS-CoV-2 infection rates in settings where active testing for virus is limited and remote sampling is optimal. We developed 12 ELISAs detecting total or antibody isotypes to SARS-CoV-2 nucleocapsid, spike protein or its receptor binding domain (RBD), 3 anti-RBD isotype specific luciferase immunoprecipitation system (LIPS) assays and a novel Spike-RBD bridging LIPS total-antibody assay. We utilised pre-pandemic (n=984) and confirmed/suspected recent COVID-19 sera taken pre-vaccination rollout in 2020 (n=269). Assays measuring total antibody discriminated best between pre-pandemic and COVID-19 sera and were selected for diagnostic evaluation. In the blind evaluation, two of these assays (Spike Pan ELISA and Spike-RBD Bridging LIPS assay) demonstrated >97% specificity and >92% sensitivity for samples from COVID- 19 patients taken >21 days post symptom onset or PCR test. These assays offered better sensitivity for the detection of COVID-19 cases than a commercial assay which requires 100-fold larger serum volumes. This study demonstrates that low-volume in- house antibody assays can provide good diagnostic performance, and highlights the importance of using well-characterised samples and controls for all stages of assay development and evaluation. These cost-effective assays may be particularly useful for seroprevalence studies in low and middle-income countries.Competing Interest StatementAF is a member of the Joint Committee on Vaccination and Immunisation, the UK national immunisation technical advisory group and is chair of the WHO European regional technical advisory group of experts (ETAGE) on immunisation and ex officio a member of the WHO SAGE working group on COVID vaccines. He is investigator on studies and trials funded by Pfizer, Sanofi, Valneva, the Gates Foundation and the UK government. This manuscript presents independent research funded in part by the National Institute for Health Research (NIHR). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.Funding StatementThis work was supported by multiple grants to AH, AL, OF, AT, IB awarded by the Elizabeth Blackwell Institute, and funded in part by the Wellcome Trust [Grant number 204813/Z/16/Z] with additional support from Bristol Alumni and Friends. AEL is funded by a Diabetes UK/JDRF RD Lawrence Fellowship (18/0005778 and 3-APF-2018-591-A-N). The DISCOVER study was supported by donations to Southmead Hospital Charity (Registered Charity Number: 1055900). ACT is supported by the Wellcome Trust (217509/Z/19/Z) and UKRI through the JUNIPER consortium MR/V038613/1 and CoMMinS study MR/V028545/1. The UK Medical Research Council and Wellcome (Grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. NJT is a Wellcome Trust Investigator (202802/Z/16/Z), is the PI of the Avon Longitudinal Study of Parents and Children (MRC & WT 217065/Z/19/Z), is supported by the University of Bristol NIHR Biomedical Research Centre (BRC-1215-2001), the MRC Integrative Epidemiology Unit (MC_UU_00011/1) and works within the CRUK Integrative Cancer Epidemiology Programme (C18281/A29019). LIPS assay development was supported by a joint grant from Diabetes UK/JDRF (20/0006217) to KMG. IB is supported by the Wellcome Trust (106115/Z/14/Z, 221708/Z/20/Z), the ERC (contr. nrs. 834631, 963992) and the EPSRC Impact Acceleration Account EP/R511663/1. We also acknowledge funding from BBSRC/EPSRC Synthetic Biology Research Centre (BB/L01386X/1, to NDB and AMT), NHS Blood and Transplant (WP15-05, to NDB and AMT), and the NIHR Blood and Transplant Research Unit in Red Cell Products (IS-BTU-1214-10032, to NDB and AMT). This publication is the work of the authors and Alice Halliday et al will serve as guarantors for the contents of this paper.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:COVID-19 cases PCR confirmed and clinically suspected COVID-19 cases were recruited via two independent routes in Bristol, United Kingdom between April and November 2020 (prior to roll out of vaccinations). PCR confirmed and clinically suspected severe COVID-19 cases admitted to hospital were recruited into the DISCOVER study at North Bristol NHS Trust for which HRA Approval was granted by the South Yorkshire Research Ethics Committee (20/YH/0121). Clinical and demographic features were recorded during the in-patient stay and subsequently at out-patient follow-up clinics. Respiratory samples were submitted for SARS-CoV-2 PCR testing on admission or first presentation; further samples were tested where initial samples tested negative for SARS-CoV-2 RNA. Serum or plasma samples were collected at various time points during in-patient and out-patient follow-up. In addition, healthcare workers (HCWs) at University Hospitals Bristol, North Bristol NHS Trust and Weston NHS Foundation Trust who had a previous positive nasopharyngeal swab for SARS-CoV-2 by PCR were invited to donate blood samples under the Bristol Biobank (NHS Research Ethics Committee Ref 20/WA/0273). A clinical data form was used to collect details of symptoms, tests and other information relating to the donor and their COVID-19 status at the point of sampling. A subset of donors was invited back for a repeat donation at >12 weeks post symptom onset. Pre-pandemic samples Samples collected prior to December 2019 were sourced from various collections held in Bristol as detailed in the Table 3 below. All samples were used in accordance with the Human Tissue Act (2004) with appropriate consent and ethical approvals in place. Samples from a longitudinal cohort of keyworkers collected during the pandemic Patient-facing clinical staff members working regularly in the Childrens Emergency Department (CED) of Bristol Royal Hospital for Children, including doctors, nurses and healthcare assistants were invited to take part in the LOGIC (LOnGItudinal Study of COVID-19: Symptoms, Virology & Immunity) study in April 2020; REC reference number 20/YH/0148. In this study, participants donated respiratory and blood samples and provided regular symptom diaries over a 12-month period. Table 3. Details of pre-pandemic samples collated from various collections including research ethics committee (REC) references, sample types and years of collection. CohortDonor typeSample TypesYear/s of collectionEthical Approval details of use and/or reference/s 1998 Blood DonorsHealthy adultsSerum199819/WA/0295 2019 Blood DonorsHealthy adultsPlasma2019NHSBT Bioresource samples approved for use by NHSBT internal review and used under REC 20/YH/0168 Avon Longitudinal Study or Pregnant women And Children (ALSPAC) cohort and healthy controlsLongitudinal cohort of children aged 7, 9, 13, 15, 17. Serum and PlasmaVarious between 1998-2017Ethical approval for the use of these samples was obtained from the ALSPAC Ethics and Law Committee and the Local RECs; Healthy control adultsHealthy control adults aged 20-60.Serum and Plasma2014Ethical approval obtained from South West Frenchay Proportionate Review Committee, Bristol, UK reference 14/SW/0087. Bristol BiobankHealthy adults and children participating in research studiesSerumVarious between 2006-2015Samples released under approved Biobank Use application (U-0042). Ethics REC reference 20/WA/0273. Pneumonia/pleural casesHospitalised adults with pleural empyema or parapneumonic effusionSerumVarious between 2009-2016Samples drawn from a prospective observational study with full REC approvals (08/H0102/11)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors